Statins not appropriate for patients with low CV risk

The management guidelines of the National Vascular Disease Prevention Alliance (NVDPA) will advocate a broadening of indications, but they will stop short of complying with calls for more widespread use of statin therapy for primary prevention prompted by a meta-analysis of studies in low risk patients.

The study, led by a collaborative group including the NHMRC Clinical Trial Centre, University of Sydney, and British researchers, found that statin therapy safely and effectively reduced the risk of major vascular events by about a fifth in a range of people with a five year CV risk lower